Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib [PDF]
, 2019 DiPersio, John F. +4 more
core +1 more source
Ruxolitinib in the treatment of patients with myelofibrosis — questions and answers
, 2019 Krzysztof Warzocha +10 more
openalex +2 more sources
Topical Ruxolitinib for the Treatment of Alopecia Universalis [PDF]
, 2015 Brittany G. Craiglow +2 more
openalex +1 more source
Intermittent and Short-Term Empirical Ruxolitinib Regimen for Steroid-Refractory Flareups of Fibrodysplasia Ossificans Progressiva. [PDF]
Pharmacol Res PerspectChen RL +4 more
europepmc +1 more source
Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis [PDF]
Sigrid Machherndl‐Spandl +11 more
openalex +1 more source
Laser-assisted drug delivery of topical ruxolitinib for treatment-refractory stable nonsegmental vitiligo: A case analyzed using noninvasive imaging modalities. [PDF]
JAAD Case RepRafiq B +4 more
europepmc +1 more source
Clinical and Immunological Impact of JAK Inhibition in Concurrent Down Syndrome and STAT1 Gain of Function. [PDF]
J Clin ImmunolBlanco-Lobo P +20 more
europepmc +1 more source
Long-term safety and effectiveness of ruxolitinib in Japanese patients with polycythemia vera: a post-marketing study. [PDF]
Future OncolHayashi T, Hongo W, Lu W.
europepmc +1 more source
Concurrent Presentation of Pure Red Cell Aplasia and Myeloproliferative Neoplasm, Unclassifiable With JAK2 and MPL Mutations. [PDF]
Case Rep HematolLi Q, Tan L, Wang X, Fan Q.
europepmc +1 more source